Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19.

ABSTRACT:

Background

Controversy remains about the efficacy of tocilizumab (TCZ) for the treatment of severe COVID-19. We aimed to analyze the profile of TCZ-respondent patients.

Methods

We retrospectively analyzed a cohort of patients with severe COVID-19 who received off-label TCZ after recommendation by a local committee and were admitted to the University Hospital "12 de Octubre" until May 2020. The primary end point was a significant clinical improvement (SCI) on day 14 after administration of TCZ. Factors independently related to SCI were analyzed by multivariate logistic regression models.

Results

Of 428 (63.3%) patients treated with TCZ, 271 (63.3%) experienced SCI. After adjustment for factors related to unfavorable outcomes, TCZ administration within the first 48 hour

SUBMITTER: San-Juan R 

PROVIDER: S-EPMC8783837 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature